Serbia’s Drugmaker Galenika Cuts Net Loss 58% to $65.8 Million

Galenika AD, Serbia’s state-run drugmaker, cut its net loss by more than half last year on reduced writedowns as its accumulated debt exceeded assets.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.